Løkkegaard Ellen, Jovanovic Zorana, Heitmann Berit L, Keiding Niels, Ottesen Bent, Hundrup Yrsa Andersen, Obel Erik B, Pedersen Annette Tønnes
Department of Obstetrics and Gynecology, Hvidovre Hospital, Copenhagen, Denmark.
Arch Neurol. 2003 Oct;60(10):1379-84. doi: 10.1001/archneur.60.10.1379.
Recent randomized clinical trials suggest an increased risk of stroke with hormone therapy (HT), whereas observational studies have suggested mixed results. Differences in design, definitions of HT exposure, and stroke outcome may explain these discrepancies. Little attention has been paid to identifying subgroups of women who are particularly sensitive to HT.
To investigate the risk of various stroke outcomes among women using HT based primarily on estradiol-17beta (unopposed or combined with norethisterone acetate) and to assess the potential modifying effect by presence of risk factors for stroke.
Prospective cohort study.
In 1993, the Danish Nurse Study was established, and questionnaires on lifestyle and HT use were sent to all Danish nurses older than 44 years, of whom 19,898 (85.8%) replied.
Postmenopausal women (n = 13,122) free of previous major cardiovascular and cerebrovascular disease and cancer.
Ischemic or hemorrhagic stroke (n = 144) identified in the national registries of hospital discharges and cause of deaths in the total follow-up through December 31, 1998.
In 1993, 28.0% of the 13 122 were current HT users, 14.3% were past users, and 57.7% were never users. Overall, HT exposure was not consistently associated with stroke. However, subdivision based on the presence of hypertension showed a significantly increased risk of stroke among hypertensive women. Compared with hypertensive never HT users, an increased risk of total stroke was found with current use (hazard ratio, 2.35; 95% confidence interval, 1.16-4.74) and especially with current use of estrogen-progestin (hazard ratio, 3.00; 95% confidence interval, 1.33-6.76). Normotensive women had no increased risk of stroke with HT.
We found an increased risk of stroke among hypertensive but not normotensive women using HT. The present study suggests that HT should be avoided in hypertensive women.
近期的随机临床试验表明激素疗法(HT)会增加中风风险,而观察性研究的结果则参差不齐。研究设计、HT暴露的定义以及中风结局的差异可能解释了这些差异。对于识别对HT特别敏感的女性亚组,关注较少。
研究主要使用雌二醇-17β(单独使用或与醋酸炔诺酮联合使用)的女性中各种中风结局的风险,并评估中风危险因素的存在对其潜在的修正作用。
前瞻性队列研究。
1993年设立了丹麦护士研究,向所有44岁以上的丹麦护士发放了关于生活方式和HT使用情况的问卷,其中19,898人(85.8%)进行了回复。
绝经后女性(n = 13,122),既往无重大心血管和脑血管疾病及癌症。
在截至1998年12月31日的整个随访期间,通过国家医院出院登记和死亡原因登记确定的缺血性或出血性中风(n = 144)。
1993年,13,122名女性中28.0%为当前HT使用者,14.3%为既往使用者,57.7%为从未使用者。总体而言,HT暴露与中风之间没有始终如一的关联。然而,根据是否患有高血压进行细分显示,高血压女性中风风险显著增加。与高血压非HT使用者相比,当前使用HT(风险比,2.35;95%置信区间,1.16 - 4.74),尤其是当前使用雌激素 - 孕激素联合制剂(风险比,3.00;95%置信区间,1.33 - 6.76)时,总中风风险增加。血压正常的女性使用HT不会增加中风风险。
我们发现使用HT的高血压女性中风风险增加,而血压正常的女性则不然。本研究表明,高血压女性应避免使用HT。